MCPPQ

General product description

• Form: Powder or crystalline solid (often off-white to beige)
• Category: Dissociative substance
• Chemical family: Arylcyclohexylamines (same class as PCP and ketamine)
• Marketed as: “Research chemical” (not approved for medical use)
• Label reliability: Low—contents may not match the name

Pharmacological profile (high-level)

Compounds in this category typically:

• Act as NMDA receptor antagonists
• Disrupt normal glutamate signaling in the brain
• Produce dissociation, altered perception, and anesthesia-like effects

Reported effects (generalized)

Lower range:

• Mild euphoria or stimulation
• Sensory distortion
• Numbness / reduced pain perception

Higher or unpredictable range:

• Strong dissociation (“out-of-body” feeling)
• Sedation or immobilization
• Confusion, paranoia, or agitation
• Hallucinations

Risks and concerns

This category is considered high-risk due to:

• Unknown purity and dosage variability
• Potential for overdose or severe CNS depression
• Psychological effects (panic, psychosis)
• Possible long duration → prolonged impairment
• Legal risks (many analogues are controlled substances)